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Abstract
Thyroid cancer shows high heritability but causative genes remain largely unknown. According to a common hypothesis the
genetic predisposition to thyroid cancer is highly heterogeneous; being in part due to many different rare alleles. Here we
used linkage analysis and targeted deep sequencing to detect a novel single-nucleotide mutation in chromosome 4q32
(4q32A.C) in a large pedigree displaying non-medullary thyroid carcinoma (NMTC). This mutation is generally ultra-rare; it
was not found in 38 NMTC families, in 2676 sporadic NMTC cases or 2470 controls. The mutation is located in a long-range
enhancer element whose ability to bind the transcription factors POU2F and YY1 is significantly impaired, with decreased
activity in the presence of the C- allele compared with the wild type A-allele. An enhancer RNA (eRNA) is transcribed in
thyroid tissue from this region and is greatly downregulated in NMTC tumors. We suggest that this is an example of an ultra-
rare mutation predisposing to thyroid cancer with high penetrance.
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Introduction
Thyroid cancer represents approximately 1% of newly diag-
nosed cancers and is the most common endocrine malignancy.
There are four main varieties of thyroid cancer, papillary (PTC),
follicular (FTC), medullary (MTC), and anaplastic (ATC). The
majority of all thyroid tumors are non-medullary thyroid
carcinoma (NMTC); either PTC (80–85%) or FTC (10–15%).
Contrary to many other cancers the incidence of NMTC is
increasing in recent decades [1,2]. While the etiology of NMTC is
not well characterized, it is clearly influenced by both genetic and
environmental factors. Among the latter, ionizing radiation,
especially exposure to fallout of radioactive iodine isotopes in
childhood strongly predisposes to PTC [3]. On the other hand,
genetic predisposition plays a major role as evidenced by case
control studies [4,5]. NMTC is mostly sporadic; however
increasingly over the past 20 years, the occurrence of NMTC
running in families has been observed [6]. Large population-based
studies investigating the familial aggregation of the disease indicate
a significantly increased risk of NMTC among first degree relatives
[7–9]. It has been estimated that 5 to 10% of all NMTC are
‘‘familial’’ [4,10]. The familial form of NMTC has been
recognized as a distinct clinical entity with a more severe
phenotype than its sporadic counterpart [11,12]. Usually the
familial NMTC pedigrees are small with 3 or fewer affected
individuals; autosomal dominant inheritance with reduced pene-
trance is usually suggested in these families. In the past these
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findings provided the rationale for linkage studies in NMTC
families, which identified at least 7 different genomic regions on
chromosomes 1q21 [13], 2q21 [14], 6q22 [15], 8p23 [16], 8q24
[17], 14q31 [18], and 19p32 [19] showing linkage peaks
presumably harboring predisposing genes. In most cases no
predisposing gene mutation has been described. Indeed, the
genetic factors influencing susceptibility to NMTC (high or
medium penentrance) remain largely unknown. In contrast,
genome-wide association studies have disclosed low-penetrance
loci predisposing to thyroid cancer [20,21]. We begin to
understand the molecular basis of this type of predisposition; at
least in one case a lincRNA is involved [22].
According to a common hypothesis the genetic susceptibility of
complex disorders such as cancer may be highly heterogeneous in
part due to many different rare alleles. Such alleles have not been
described in thyroid cancer. We present here an example of such
an allele. We identified a large US mid-western family with 13
individuals diagnosed with NMTC in three generations. We
conducted genome-wide linkage analyses and found strong
evidence of linkage at chromosome 4q32. We show that a long-
range enhancer element is present within the linkage peak. A
single nucleotide mutation (4q32 A.C) affects the binding of
transcription factors POU2F1 (also called OCT1) and YY1 to a
DNA motif in the enhancer and significantly alters the luciferase
reporter activity. Moreover, an enhancer RNA (eRNA) was
detected in normal thyroid tissue in the mutation region and the
eRNA expression level was strongly reduced in NMTC tumors.
Taken together, evidence from linkage, chromatin signature,
luciferase reporter assays, and gene expression analysis suggested
a long-range enhancer at 4q32 as a candidate genetic factor for
the high penetrance PTC predisposition in the family. The
mutation is ultra-rare not having been found in databases, 38
other familial NMTC kindreds, sporadic thyroid cancer patients,
or controls.
Results
Genome-Wide Linkage Analysis Revealed a Novel Locus
on 4q32
The family is an unusually large NMTC kindred with 13
individuals affected with NMTC in at least 3 generations,
including 11 cases of PTC (4 follicular variant and 7 conventional)
and 2 cases of anaplastic thyroid carcinoma (ATC) (Figure 1).
Genome-wide linkage analysis with SNP arrays revealed a locus on
chromosome 4q32, with a linkage interval of about 4.6 Mb (from
155.67 cM to 168.2 cM, deCODE map). Multipoint non-para-
metric linkage analysis yielded a maximum NPL Z-score of 18.5
(see Text S1, Figure S1). To fine map the 4q32 locus, we
genotyped 11 microsatellite markers in 22 family members,
including 10 individuals with PTC, 4 with benign thyroid disease
(two of whom are obligate carriers), and 8 unaffected family
members (3 related by marriage) (Figure 1). A shared haplotype
segregated with the disease phenotype (thyroid cancer) in all but
one affected family member. The haplotype was also found in 4
individuals with benign thyroid disorders; two of whom are
obligate mutation carriers. These benign disorders include one
case of thyroid adenoma, one case of multinodular goiter and
chronic lymphocytic thyroiditis, one case with chronic lympho-
cytic thyroiditis, and one case with focal stromal fibrosis. The
haplotype was not present in 7 out of 8 unaffected individuals
(Figure 1).
DNA Resequencing Identified an A.C Mutation in the
4q32 Locus
Genes within the 4q32 locus include known protein-coding
genes (CPE, KLHL2, ANP32C, SC4MOL, and TLL1) and several
uncharacterized transcripts and ESTs (Figure S2). To identify the
causal DNA variants/mutations in the locus, we first Sanger
resequenced the exons and exon-intron boundaries of all
annotated genes. No likely disease-causing DNA changes were
found. This prompted us to resequence the entire linkage and
flanking regions (,4.1 Mb) using deep sequencing technology (see
Text S1). We enriched the non-repetitive genomic DNA sequences
using the SureSelect Target Enrichment system (Agilent) and
prepared custom paired-end libraries from captured DNA for
deep sequencing using the Illumina HiSeq2000 platform. A total
of four affected individuals in the family were sequenced as
denoted in Figure 1.
To distinguish potentially causal variants/mutations from other
variants, we focused only on DNA changes that were shared by the
4 affected individuals and were previously unreported or reported
with very low frequency. We found a single relevant-appearing
nucleotide change at chr4:165491559 (GRCh37/hg19) in an
intergenic region and named it 4q32A.C. We then used Sanger
sequencing to examine all the 22 available samples as described
above (Figure 1). The 4q32A.C change was present in all affected
individuals and segregated with the disease phenotype except for
the one family member with PTC who did not show linkage
(individual #IV-4). To exclude sampling error or other pre-
analytical errors, we Sanger sequenced a second independent
blood genomic DNA sample from this patient; the mutation was
not found. The 4q32A.C change was also found in 4 individuals
with benign thyroid disease and one unaffected individual, but was
not present in 7 other unaffected individuals. The 4q32A.C
inheritance pattern is consistent with the haplotype analysis using
microsatellite markers (Figure 1). For one ATC patient (III-3), we
sequenced and genotyped her husband (III-2) and her two
daughters, one with PTC (IV-2) and one unaffected (IV-3).
Haplotype analysis of these individuals demonstrated that this
ATC patient was an obligate carrier of the mutation and the
haplotype, since it is present in her affected daughter and her
affected siblings but not present in her unrelated spouse (Figure 1).
The 4q32A.C change is not reported in public databases
(dbSNP and 1000 Genomes Project). We screened an additional
38 NMTC families (Figure S3), an Ohio cohort of 800 cases/820
controls, and a Polish cohort of 1876 cases/1650 controls. None of
these samples showed the 4q32A.C change. We view the
4q32A.C as an ultra-rare variant or a ‘‘private’’ mutation.
Identification of a Long-Range Enhancer in the Mutation
Region
The 4q32A.C mutation is located in an intergenic region
where the closest known genes are MARCH1 located ,190 kb
upstream and a non-coding RNA gene (NR_038834) located
,190 kb downstream (Figure 2, Figure S2). We examined
comparative genomics data and the ENCODE histone marker
data in the UCSC genome browser (Figure S4) and found that the
sequence in the 4q32A.C region is highly conserved among
mammals, suggesting regulatory element(s) in the region. We then
used the enhancer element locator (EEL) computer program to
screen for potential evolutionarily conserved enhancer elements
[23]. An enhancer element spanning the 4q32A.C mutation site
was predicted by the computer analysis (Table S1).
Since the mono-methylation at histone 3 lysine 4 (H3K4me1)
and transcriptional co-activators (p300 and MED1) can accurately
Enhancer Mutation Predisposes to Thyroid Cancer
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predict enhancer activity at many loci, we performed site-directed
ChIP assays for H3K4me1, P300 and MED1 of lymphoblastoid
cell lines established from one thyroid carcinoma patient with the
4q32A.C heterozygous genotype and one control with the wild
type A/A genotype. We observed strong enrichment of enhancer
mark, e.g.H3K4me1 and robust occupancy of transcriptional co-
activators (p300 and MED1) in this region in the control
lymphoblastoid cell line (Figure 3). These observations provided
independent evidence for the likelihood of strong in vivo enhancer
activity from this region. Importantly, these patterns of activity
were significantly decreased in the mutant cell line (Figure 3),
implying that the enhancer activity is likely damaged or destroyed
by the 4q32A.C mutation. To validate these findings, we
performed the same assays in a second patient cell line and a
control cell line and obtained very similar results, supporting that
the enhancer activity is likely damaged or destroyed by the
4q32A.C mutation.
Functional Impact of the 4q32 Mutation on Enhancer
Function
To establish whether the 4q32A.C mutation within the
enhancer corresponds to a functional binding site of a known
transcription factor, we screened the mutant nucleotide and the
adjacent DNA sequence using the TRANSFAC database [24] and
identified a composite motif consisting of a potential binding site
for transcription factors POU2F1 and YY1 (Figure S5). We
hypothesized that the mutant nucleotide might alter transcription
factor binding to the 4q32 enhancer and lead to a detectable allele-
specific functional effect on transcription. To test this hypothesis,
we amplified a 700 bp DNA fragment containing the 4q32A.C
mutation using a patient’s DNA and cloned the sequence into a
luciferase reporter construct driven by a minimal promoter vector.
We obtained constructs harboring the wild type A-allele and the
mutant C-allele of the 4q32 enhancer, respectively. Enhancer
activities were determined by transient transfection and luciferase
assays in the thyroid cancer cell line BCPAP. The wild type A-
allele had the most pronounced enhancer activity in the presence
Figure 1. A thyroid cancer susceptibility locus in 4q32. Pedigree showing haplotypes of the family across the 4q32 region. The shared
haplotype is boxed. The DNA samples from 4 affected individuals studied by targeted deep sequencing are marked ‘‘Seq’’. One PTC individual who
does not share the haplotype and does not have the 4q32A.C mutation is marked ‘‘#’’.
doi:10.1371/journal.pone.0061920.g001
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of a POU2F1 expression construct, while the mutant C-allele
showed significantly decreased activity (Figure 4A). We did not
observe any effect on the luciferase activity in the presence of YY1
expression construct alone; however, co-transfection of POU2F1
and YY1 significantly inhibited the enhancer activity, compared
with that in the presence of the POU2F1 expression construct
alone. Moreover, the mutant C-allele showed significant reduction
of the luciferase activity in the presence of both POU2F1 and YY1
(Figure 4A). We observed very similar patterns of luciferase
reporter activities in the HeLa cell line (Figure S6). These results
indicated that the presence of the mutant nucleotide (C-allele) in
the enhancer fragment significantly altered the expression of firefly
luciferase, suggesting that the chr4 site functions as an allele-
specific long-range enhancer and the transcription factors
POU2F1 and YY1 are involved in the enhancer activity.
To validate the binding of POU2F1 and YY1 to the enhancer
and the disruption of POU2F1 occupancy at the mutated C-allele,
we performed ChIP assays and found that the POU2F1 binding
was enhanced in the presence of the wild type A/A genotype in a
control cell line whereas the binding was significantly reduced in a
heterozygous A/C patient cell line (Figure 4B). The binding
intensities of YY1 showed a pattern similar to POU2F1, that is, the
patient cell line with a heterozygous A/C change showed reduced
YY1 binding compared with the control cell line with wild type A/
A genotype. We performed the same assays in a second patient cell
line and a control cell line and obtained very similar results.
Collectively, results of ChIP experiments and luciferase reporter
assays are consistent with the hypothesis that the chr4 locus
harbors an intergenic long-range enhancer. The 4q32 A.C
mutation appears to destroy the intrinsic enhancer activity in
thyroid cells and possibly other tissues.
Transcription at the 4q32 Enhancer and Deregulated
Transcription in PTC Tumors
To further characterize the 4q32 enhancer, we examined
enhancer RNA (eRNA) expression using semi-quantitative RT-
PCR. Indeed the 4q32 enhancer produced RNA in normal
thyroid tissue (a 134 bp amplicon) (Figure S7). The detection of
eRNA in thyroid was not due to the residual genomic DNA that is
often present in purified RNA samples, since there was no eRNA
detected in the absence of reverse transcriptase. We also detected
the 4q32 eRNA in cDNAs derived from human breast, colon,
liver, lung, brain, and fetal brain tissue; but not in cDNA derived
from kidney (Figure 5A). In addition, we examined the 4q32
eRNA levels in thyroid tumors obtained from 9 sporadic PTC
patients and compared them with the matched non-affected
thyroid tissue from the same patients. The eRNA level was clearly
reduced or undetectable in 7 out of 9 tumor samples using a semi-
quantitative RT-PCR assay (Figure 5B).
Discussion
It is increasingly clear that human populations harbor an
abundance of rare variants some of which are deleterious
contributing to disease risk [25]. We report here an ultra-rare
mutation (4q32A.C) in a large family as the putative causal
variant predisposing to non-medullary thyroid cancer. In this
particular family, we confirmed this rare mutation in 9 PTC
patients and showed that one of the two ATC patients was an
obligate carrier of the mutation. ATC is the most aggressive
thyroid gland malignancy that is often believed to evolve from
PTC [26,27]. We interpret these findings to suggest that the
4q32A.C mutation is involved in the predisposition to both PTC
and ATC in this family. Linkage analysis and co-segregation data
suggested relatively high penetrance, and notably, the variant was
not found in 38 additional NMTC pedigrees. In addition, it was
not found in,2500 sporadic PTC cases and ,2500 controls from
two populations, suggesting that this is an ultra-rare, perhaps
private mutation. We cannot exclude the existence of other
regulatory sequences in the region predisposing to NMTC.
Comprehensive enhancer screening in this region is called for.
In addition to those individuals diagnosed with NMTC in the
family the 4q32A.C mutation was detected in 4 individuals with
benign thyroid disease (two were obligate carriers), which is
consistent with previous suggestions that thyroid malignancy and
benign thyroid lesions may share the same genetic background
under certain circumstances [14,17]. We also found one unaffect-
ed individual carrying the 4q32A.C mutation, and conversely,
one individual with PTC who did not carry the mutation. This is
Figure 2. A 4q32A.C mutation in an intergenic region in a large family. Diagram of chromosome 4 showing the area of linkage (boxed)
targeted for deep sequencing and the location of the 4q32A.C mutation. Chromosome 4 coordinates and schematic of genes were drawn based on
information from UCSC Genome Browser GRCh37/hg19 (not all genes are shown).
doi:10.1371/journal.pone.0061920.g002
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consistent with other inherited cancer susceptibility syndromes
which are often characterized by age-related, incomplete pene-
trance and the presence of phenocopies [28,29]. Thyroid cancer in
this family may result from a combination of genetic, environ-
mental, and lifestyle factors, many of which are unknown.
Nevertheless, our data suggest that the risk associated with
NMTC in this large family is explained by an ultra-rare or
‘‘private’’ A.C mutation in the 4q32 locus. Our work supports
the long-established idea that multiple rare variants could be
important drivers of common diseases [30–35]. This may also
contribute to the genetic heterogeneity observed in thyroid cancer
predisposition [36].
Increasingly, data are accumulating to suggest that non-coding
variants underlie the increased risk of various common diseases
[37,38]. Transcriptional regulatory elements may represent major
sites where mutations contribute to human disease [39,40]. As
outlined in the Introduction, high-penetrance genes detectable e.g.
by traditional linkage analysis and shared by thyroid cancer
families may be uncommon. However our previous linkage and
genome-wide association studies have suggested that at least a
fraction of the underlying genetic variation associated with NMTC
is non-protein coding in nature [17,22]. In the family presented
here, the mutation is located in a long-range enhancer region.
Variations in enhancer sequences have been associated with
greater risk of several cancers [41–48]. For example, the 8q24
locus for colon and prostate cancer appears to harbor enhancers
potentially regulating the expression of c-Myc located ,300 kb
away [44,49]. Similarly, SOX9 has a long-range regulatory
element located over 1 Mb from the coding sequence. Genetic
variants in the long-range enhancer of SOX9 account for the risk
associated with prostate cancer [42]. Common genetic variants at
the 11q13.3 renal cancer susceptibility locus influence binding of
HIF to an enhancer of cyclin D1 expression [43]. Our finding of a
4q32 enhancer in a thyroid cancer family emphasizes the
importance of the role of non-coding regulatory sequences in
cancer and the importance of sequencing the entire candidate
regions or whole genome when searching for causal variants/
mutations in diseases.
Transcriptional regulation is a highly organized process that
directs gene expression in response to developmental and signaling
events. Disruption of either of these may lead to disease and is
certainly known to be associated with malignancy [50,51]. Key to
this control is the recruitment of transcription factors that bind to
regulatory sequences, such as enhancer elements. In 4q32, ChIP
assays showed that both POU2F1 and YY1 bound to the mutation
region and showed decreased binding to the mutant allele
compared with the wild type allele. Consistently, we found that
the A.C mutation has functional effects in the presence of
POU2F1 alone and in the presence of both POU2F1 and YY1
using a luciferase reporter assay. POU2F1 and YY1 are
ubiquitously expressed transcription factors that mediate cell-
type-specific and temporally restricted gene expression [52]. Both
POU2F1 and YY1 are expressed in normal thyroid tissue; they
also are involved in the transcription of thyroid specific genes and
in thyroid development [53]. We observed decreased binding of
POU2F1 and YY1 to the 4q32A.C mutation within the 4q32
locus, which could lead to altered expression of its target gene(s)
and to increased susceptibility to NMTC. Many long-range
enhancers are tissue-specific and activate their target promoters
over long distances, sometimes even on different chromosomes
[54]. So far the target genes of most of these enhancers are
unknown. We cannot assess how likely, e.g., the neighboring
genes, such as MARCH1 or a noncoding RNA gene (NR_038834)
might be targets of the eRNA we detected. Systematic assessment
of the target gene(s) and their roles in NMTC will be of great
future interest. We anticipate that finding target genes relevant to
thyroid cancer may be a complex undertaking given the
documented multi-organ expression pattern of the eRNA we
detected.
In summary, we describe an ultra-rare mutation (4q32 A.C) in
a long-range enhancer in a large kindred as a candidate cause of
cancer predisposition. Moreover, 4q32 eRNA was detected in
normal thyroid tissue and downregulated in thyroid tumor tissue
suggesting an involvement of this regulatory element not only in
the described family but in sporadic PTC as well. Our finding
Figure 3. The 4q32A.C mutation is associated with reduced
levels of enhancer markers. ChIP assays of lymphoblastoid cell lines
established from a control individual (4q32-A/A) and a PTC patient in
the family (4q32-A/C). Antibodies against H3K4me1, P300, and MED1
were used in the assays. **: p-value,0.01; *: p-value,0.05. Error bars
represent 6SD of at least three independent experiments.
doi:10.1371/journal.pone.0061920.g003
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Figure 4. The 4q32A.C mutation leads to reduced enhancer activity and POU2F1 and YY1 binding. (A) Luciferase assays of the
enhancer activity using the thyroid cancer cell line BCPAP. **, p-value,0.005. (B) ChIP assay for transcription factors POU2F1 and YY1 using
antibodies against POU2F1 and YY1 in lymphoblastoid cell lines. The control and patient cell lines are the same as in Figure 2. **, p-value,0.01. Error
bars represent 6SD of at least three independent experiments.
doi:10.1371/journal.pone.0061920.g004
Figure 5. The 4q32 eRNA is expressed in multiple tissues and shows strong downregulation in thyroid tumors. (A) Detection of the
4q32 eRNA in normal human tissues. (B) Semi-quantitative assay of the 4q32 eRNA in paired tumor and unaffected tissue from 9 PTC patients. Total
RNA was used for cDNA synthesis; GAPDH was used as an internal control. The primers for the amplicons of the eRNA and GAPDH are provided in
Supplementary Table 2.
doi:10.1371/journal.pone.0061920.g005
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provides novel insight into the complexity and heterogeneity of the
genetic architecture underlying non-medullary thyroid cancer.
Materials and Methods
Ethics Statement
The studies were approved by the Institutional Review Board at
the Ohio State University, and all subjects gave written informed
consent before participation.
Family Samples and Genomic DNA Extraction
The pedigree of the family is depicted in Figure 1. This large
family is of Caucasian, non-Hispanic origin and resides mainly in
the mid-western region of the US. The clinical information and
family history of all the recruited family members were reviewed.
None of the family members have a history of ionizing radiation
exposure or any other common environmental exposure that
might explain the high rate of thyroid cancer in this family. The
histological diagnoses of PTC in 6 PTC patients (II-4, III-4, III-8,
III-11, IV-2, and IV-6) were confirmed by re-evaluating the tumor
slides by an expert pathologist at the OSU Medical Center. For
the 2 cases of ATC in this family (III-1 and III-3), unfortunately,
the slides/blocks were not available. The available pathology
reports indicated highly invasive and aggressive tumors originating
in the thyroid gland in both affected individuals. The tumors had
invaded the trachea and esophagus. Both individuals died of their
disease within 5–12 months of their diagnosis. An additional 38
families with NMTC in close relatives were also studied. The
pedigrees of these smaller kindreds are provided in Figure S3.
Family history information, pathology reports confirming the
diagnosis of thyroid cancer or thyroid disease, as well as blood and
tissue samples were collected from all consenting affected
individuals and key unaffected individuals. Genomic DNA was
extracted from blood according to standard phenol-chloroform
extraction procedures.
Genotyping and Sanger Sequencing
Genotyping and Sanger sequencing were carried out using
standard protocols as described [17]. The PCR primer sequences
are provided in Table S2. The PCR assays were performed
according to a standard protocol as follows: 2 min at 94uC;
followed by 30 cycles of 30 s at 94uC, 30 s at 58uC, and 30 s at
72uC; followed by a final extension of 10 min at 72uC. An ABI
3730 DNA Analyzer was used for either the allele analysis or
Sanger sequencing.
Thyroid Samples and Genomic DNA and RNA Extraction
Fresh snap-frozen thyroid tissue was obtained from patients
with sporadic PTC undergoing surgical resection. Control
‘‘normal’’ thyroid tissue was collected from consenting individuals
who had surgery because of laryngeal malignancy but no thyroid
disease. Clinical data and information on the specimens will be
provided upon request. The fresh frozen tissues were selected for
study after histological examination. Genomic DNA was extracted
by a standard phenol-chloroform procedure. Total RNA from
fresh frozen tissue was extracted with TRIzol Reagent (Invitro-
gen).
Semi-quantitative RT-PCR
Total RNA was first treated with DNase-1 (Ambion) and then
reverse transcribed to cDNA with the SuperScript First Strand
Synthesis system (Invitrogen). Candidate genes and an endogenous
control gene, glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) were included in the same PCR reaction for semi-
quantitative RT-PCR. All PCR assays were verified to be in the
linear range by testing with different cycle numbers.
Constructs, Cell Culture, Transient Transfections, and
Luciferase Reporter Gene Assays
For enhancer-reporter gene assays, a 700 bp intergenic DNA
sequence containing the wild type A or mutant C allele in the 4q32
enhancer was PCR amplified and cloned into PGL4.10-E4TATA
vector, which contains a 50 bp minimal E4 TATA promoter
sequence. These constructs were validated by Sanger sequencing.
The BCPAP cell line was incubated in antibiotic-free RPMI1640
medium supplemented with 10% fetal bovine serum at 37uC in
humidified air with 5% CO2. Co- transfection with empty vector
or the enhancer constructs, POU2F1 and/or YY1 expression
constructs, and a renilla luciferase reporter plasmid were
performed. The empty PGL4.10-E4TATA vector DNA was
added if necessary to make sure the same amount of total DNA
was used for transfection in all groups. Cells were harvested after
24 h and lysates were used for luciferase assays. At least three
independent experiments were performed.
Quantitative Chromatin Immunoprecipitation (ChIP)
Assay
ChIP was performed as previously described [55] with minor
modification. Briefly, the Protein-DNA cross-linking was per-
formed by incubating cells with formaldehyde at a final
concentration of 1% for 10 min at room temperature. After
sonication, chromatin was immune precipitated with specific
antibodies at 4uC overnight. The antibodies anti-p300 (sc-585),
anti-MED1 (sc8998), anti-YY1 (sc-281) and anti-POU2F1 (OCT1)
(sc-232) were from Santa Cruz Biotechnology; Anti-H3K4me1
(ab8895) was from Abcam. The Immune complexes were then
eluted from the beads and the cross-links were reversed by
incubating at 65uC overnight. The DNA was purified with
QIAquick PCR purification kit and used as the template in
quantitative PCRs. Primers were designed to yield amplicons
ranging in length from 70–110 bp which spanned the mutation
region (Table S2).
Supporting Information
Figure S1 Linkage plots in the large thyroid cancer
family. (A) Genome-wide linkage analysis with MERLIN; plot of
non-parametric linkage (NPL) Z-score in chromosomes 1 to 22. (B)
Plot of NPL Z-score in chromosome 4. The linkage peak in
chromosome 4 is marked with an arrow.
(TIF)
Figure S2 The genomic region and genes in 4q32 locus.
Information is obtained from UCSC genome browser (GRCh37/
hg19). The position of the 4q32A.C is marked with an arrow.
(TIF)
Figure S3 Simplified pedigrees of 38 families with
NMTC cases. Members affected with PTC are indicated by
filled solid circles or squares. Hatched circles or squares denote
those with benign thyroid disease. Open circles: unaffected. For
family #26, two members with PTC and melanoma are indicated
with two asterisks (**); two members with melanoma only are
indicated with one asterisk (*).
(TIF)
Figure S4 ENCODE histone marker and comparative
genomics data from the UCSC genome browser
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(NCBI36/hg18). The genomic region encompasses 700 bp; the
4q32A.C mutation is marked with an arrow.
(TIF)
Figure S5 DNA motifs consisting of potential binding
sites for transcription factor YY1 and POU2F1. (A)
Sequencing chromatogram showing the 4q32A.C mutation with
DNA sample of a PTC patient; the DNA motif is boxed. (B) The
DNA motifs with the wild type A-allele and mutant C-allele in the
4q32 A.C region.
(TIF)
Figure S6 Luciferase assays showing reduced enhancer
activity with the mutant C-allele. HeLa cells were transiently
co-transfected with reporter constructs containing the wild type A-
allele or the mutant C-allele with POU2F1 or YY1 constructs.
Data shown are the average of at least three experiments. *, p
value,0.005. Error bars represent 6SD of at least three
independent experiments.
(TIF)
Figure S7 4q32 eRNA. (A) The relative position of the eRNA.
(B) Detection of 4q32 eRNA in normal thyroid tissues by RT-
PCR. M, size marker; (2), no template; RT (2), absence; RT (+)
presence of reverse transcriptase. Total RNA was used for cDNA
synthesis; GAPDH was used as an internal control. The primers for
the amplicons of the eRNA and GAPDH are provided in Table S2.
(TIF)
Table S1 Alignment result with Enhancer Element
Locator program in the 4q32A.C region.
(DOCX)
Table S2 Primers used for sequencing, SNaPshot assay,
RT-PCR, and ChIP assay.
(DOCX)
Text S1 Supplemental Methods.
(PDF)
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